Please assess the completion status of the following clinical trial:

Trial Title: Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal status~* Subject should have had a minimum of 7 moderate to severe hot flushes per day, or a minimum of 50 moderate to severe hot flushes per week, during the last 2 weeks of the run-in (screening) period.~* Subject with an intact uterus~Exclusion Criteria:~* In accordance with existing labelling for estrogen/progestogen combinations~* Body Mass Index (BMI) \> 35.0 kg/m2~* Known alcohol or drug abuse, heavy smoking (more than 20 cigarettes a day)~* Currently using steroid hormones (except topical or inhalation glucocorticoid preparations) and drugs known to influence estrogen metabolism such as barbiturates, phenytoin, rifampicin, carbamazepin

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ALD 0.1 (Type: EXPERIMENTAL): None
- ALD 0.25 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).